Dermatology

Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ. A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Poster presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.


OBJECTIVE: To develop a cost-per-responder (CPR) analysis for ritlecitinib and baricitinib for the treatment of severe AA to address uncertainties in budget impact of these new therapies resulting from differences in clinical efficacy and available dosages.

Blauvelt A, Reckleff J, Zhao Y, Clark M, Kosa K, Harris N, Esfandiari E, Martin S, Whalley D, Emma GY. Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews. Br J Dermatol. 2024 Oct 4. doi: 10.1093/bjd/ljae346


Kohli RK, Hawe E, Harold S, Simou E, Chrysos AE, Orfanos P. Utility scores in chronic spontaneous urticaria: a systematic literature review and statistical analysis. Poster presented at the European Academy of Dermatology & Venereology (EADV) Congress 2024; September 25, 2024. Amsterdam, Netherlands.


INTRODUCTION AND OBJECTIVES: Chronic spontaneous urticaria (CSU) has a substantial impact on patient health-related quality of life (HRQoL). This study aims to document published utility values associated with CSU health states and derive new CSU health-state utility scores using recent randomized clinical trial (RCT) data.

Tavi J, Bahloul D, Kuznik A, Thomas RB, Knight C, Manga N, Sullivan SD. Economic evaluation of dupilumab versus standard of care for the treatment of adult patients with moderate-to-severe prurigo nodularis in the United States. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S104. doi: 10.1016/j.jval.2024.10.543


BACKGROUND: Dupilumab, currently the only approved systemic therapy for prurigo nodularis (PN), may be given on top of standard-of-care (SOC) treatments (e.g., topical corticosteroids and calcineurin inhibitors).

Bhutani T, Jayade S, Rege S, Penton H, Patel V, Kalirai S, Wolin D, Boyle K, Seigel L. Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey. J Dermatolog Trea. 2024 Jun 24;35(1):2366532. doi: 10.1080/09546634.2024.2366532


PURPOSE: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis.

Armstrong AW, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, Wolin D, Boyle K, Patel D, Seigel L. Evaluating treatment choice in patients with moderate to severe psoriasis in the United States: results from a US patient survey. Dermatol Ther. 2024 Feb;14(2):421-39. doi: 10.1007/s13555-023-01089-6


Blauvelt A, Reckleff J, Zhao Y, Clark M, Kosa K, Harris N, Esfandiari E, Martin S, Whalley D, Emma GY. Content evaluation of pruritus, skin pain, and sleep disturbance patient-reported outcome measures in adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews. Br J Dermatol. 2025 Jan 24;192(2):247-60. doi: 10.1093/bjd/ljae346


Maeda-Chubachi T, McLeod L, Cartwright M. Meaningful change in children's dermatology life quality index (DLQI) and lesion counts in patients with molluscum contagiosum. Poster presented at the First International Societies for Investigative Dermatology (ISID2023) Meeting; May 10, 2023. Tokyo, Japan. [abstract] J Invest Dermatol. 2023 May; 143(5 Suppl):S105. doi: 10.1016/j.jid.2023.03.622


BACKGROUND: Health-related quality of life evaluation is scarce in patients with molluscum contagiosum (MC) & little is known about the meaningfulness of lesion count reduction.

Maeda-Chubachi T, McLeod L, Enloe C, Cartwright M, Siegfried E, Hebert AA, Silverberg N. Defining clinically meaningful improvement in molluscum contagiosum. J Am Acad Dermatol. 2024 Feb;90(2):443-5. doi: 10.1016/j.jaad.2023.10.033


BACKGROUND: Health-related quality of life evaluations are scarce in patients with molluscum contagiosum (MC).

OBJECTIVE: To understand perceptions of MC severity and meaningfulness of MC lesion count reduction.

Pandya AG, Amoloja T, Bibeau K, DiBenedetti D, Kosa K, Butler K, Kornacki D, Ezzedine K. Assessing participants' experiences with vitiligo from patient interviews. Dermatol Ther. 2024 Sep;14(9):2467-78. doi: 10.1007/s13555-024-01241-w


INTRODUCTION: Vitiligo is an autoimmune disease causing skin depigmentation in the form of white patches. Individuals with vitiligo incur substantial psychosocial burden and have expressed frustration with their treatments.

Subscribe to Dermatology

How Can We Help You?